After $800 million typo, Valeant CEO is back on the hot seat

Doni Bloomfield, Cordell Eddings and Cynthia Koons

Mar 16, 2016 – 10.23am

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Michael Pearson and his company, Valeant Pharmaceuticals International, were supposed to calm Wall Street doubters on Tuesday. Instead: chaos.

What began before dawn with disappointing financial news quickly snowballed into the worst day in the drug company's history, leaving investors wondering if Pearson, its controversial chief, can regain his grip.

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Introducing your Newsfeed

Follow the topics, people and companies that matter to you.

Fetching latest articles